Process Development of ADCs and Bioconjugates

This webinar focuses on critical design and process development steps to ensure the optimization and scale-up of ADCs and bioconjugates. By starting smart, we can finish fast and maximize chances of success.

It covers the following areas:

Designing Next Generation Bioconjugates

• Selecting Target and Targeting Moiety
• From Linker-Payload to Conjugate

Process Development and Manufacturing Considerations for Next-Gen Conjugates

• Incorporating Next-Generation Conjugation Technologies into ADC Manufacturing – Engineered Cysteines ADCs​
• Manufacturing Strategies for Novel Payloads Conjugates – Radioimmunoconjugates and Oligonucleotides Conjugates

Learning Objectives:

• Considerations for designing next-generation bioconjugates.
• Process development and manufacturing considerations for next-generation conjugates.

About Our Speakers

Dr Saptarshi Ghosh, Principal Scientist, Bioconjugation

• Principal scientist at Abzena focusing on Early to Late Phase bioconjugation development and manufacturing of ADCs.
• R&D lead for novel-format bioconjugation strategies and development.
• Led projects for integrated programs supporting batch execution, tech transfer and providing manufacturing support for ADCs.
• Background in chemical biology, bioconjugation and biorthogonal chemistry
• Doctoral work in the field of biorthogonal chemistry, working with novel intramolecular lewis acid catalyzed click reactions.
• Developed novel strategies to combine enzymatic and click reactions in single vessel immunoprecipitation of proteins.
• Ph. D.  in Chemistry from State University of New York at Binghamton.

Austin McKinsey, Senior Bioconjugation Scientist

Bioconjugation expert with 3 years of experience in ADC process development and ADC manufacturing.

• Manager at Abzena focusing on Process Development and Manufacture of Bioconjugate Therapies.
• Supporting manufacturing and process development for ADCs and novel-format bioconjugate modalities.
• Development and Manufacture lead for over 8 ADC, Protein-Oligonucleotide conjugates, and Radio-immunoconjugates currently in clinical trials.
• Background in viral vector mediated gene-therapy process development and manufacturing.
• Platform development for upstream and downstream processes for AAV and Lenti viral vectors at Wuxi Advanced Therapies
• Bachelors in Pharmacology and Toxicology from University of the Sciences